




Molecular signature for the assessment of aggressiveness of localized prostate cancer



MARKET CHALLENGES

Prostate cancer (PC) is characterized by unregulated and uncontrolled cell growth and division. It is one of the most frequent cancer diagnosed in men in developed countries, accounting for around 8% of all new cancer cases and 15% in men.

Management of localized PC is a major clinical challenge. Indeed, the majority of prostate cancers won't evolve and are exposed to overtreatment, on the other hand a set of prostate cancers at early stage are potentially lethal and are exposed to undertreatment.

However, the medical community still lacks efficient tools or markers to classify PC accordingly and accurately identify aggressiveness of cases.

SUGGESTED APPLICATIONS

- Therapeutic strategy for localized prostatic adenocarcinomas based on molecular assessment of aggressiveness (Prognosis)

DEVELOPMENT STATUS

The molecular signature was obtained from a cohort of 193 patients (130 subjects with localized PC and 63 subjects with adjacent normales prostate).

INNOVATIVE SOLUTION

A team from Sorbonne Université has developed a method for predicting the risk of prostate cancer recurrence in a subject affected with prostate cancer.

More precisely, they have developed a kit comprising a set of 39 transcriptomic biomarkers which robustly identify a subtype of non-evolutive cases preventing from overtreatment.

COMPETITIVE ADVANTAGES

- Stratification among prostate cancer subject
- Statistical relevance

IP RIGHTS

Priority patent application filed in 2018